Omalizumab models
Model name Cases included Variables included Final variables P-value OR; 95 CI AUC of model
Omalizumab response vs non-response
78/104, 75%
Clinic FEV1%, Age, BMI, Sex, Baseline annualised rate of exacerbations, Multiple AHE, Annualised rate of AHE, Anxiety.
Baseline annualised rate of exacerbations
0.024
1.622 (1.065-2.469)
0.856
Lower baseline annualised rate of AHE 0.050 1.297 (1.000-1.681)
No Anxiety 0.008 8.772 (1.745-43.478)
Omalizumab super-response vs non-super-response 75/104, 72.1% Baseline annualised rate of exacerbations, Multiple AHE, on mOCS, Adult onset, Obesity, ICU admission for asthma ever, Anxiety, Depression. Not on maintenance OCS <0.001 18.182 (4.484-71.429) 0.809
No Depression 0.009 4.784 (1.623-29.412)
Mepolizumab models Mepolizumab models Mepolizumab models Mepolizumab models Mepolizumab models Mepolizumab models Mepolizumab models
Model name Cases included Variables included Final variables P-value OR; 95 CI AUC of model
Mepolizumab responders vs non-responders 42/58, 72.4% ACQ6, Multiple AHE, Depression, Anxiety, AQLQ baseline, Total HADS baseline, Baseline annualised rate of AHE, Dysfunctional Breathing. Lower ACQ6 at baseline 0.007 4.651 (1.513-14.286) 0.859
Mepolizumab super- responders vs non-super-responders
47/58, 81%
Baseline annualised rate of exacerbations ACQ6, Clinic FEV1%, AQLQ baseline, BMI, on mOCS, Adult onset, Atopy, Smoking ever, Bronchiectasis ever
Lower ACQ6 at baseline
0.025
3.401 (1.167-9.901)
0.811
Baseline annualised rate of exacerbations 0.023 1.487 (1.046-2.115)